Clinical trial
A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With…
NCT00292448 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00292448 |
|---|---|
| Title | A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD) |
| Official title | A Randomised, Double-blind, Double-dummy, Crossover Efficacy and Safety Comparison of 4-week Treatment Periods of Ba 679 BR Respimat® 5 μg and Tiotropium Inhalation Capsule 18 μg in Patients With COPD |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pulmonary Disease, Chronic Obstructive |
| Intervention type | Drug |
| Interventions | Ba 679 BR Respimat, Tiotropium (Spiriva) inhalation capsule 18 ug |
| Enrollment | 157 |
| Start date | Feb 1, 2006 |
| Completion | Mar 1, 2007 |
| First posted | Feb 16, 2006 |
| Last update posted | Oct 29, 2013 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: